Eticovo (etanercept-ykro) Approved for Arthritis, Spondylitis, and Plaque Psoriasis
Eticovo (etanercept-ykro) is a TNF blocker, biosimilar to Enbrel (etanercept).
Eticovo (etanercept-ykro, Samsung Bioepis) is a tumor necrosis factor (TNF) blocker indicated for the treatment of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (JIA) in patients aged 2 years or older, psoriatic arthritis (PsA), ankylosing spondylitis (AS), and plaque psoriasis (PsO) in patients 4 years and older.
The drug is contraindicated for patients with sepsis and is packaged with a serious warning of potential infections and malignancies including tuberculosis, bacterial sepsis, invasive fungal infections, and infections due to other opportunistic pathogens.
The most common adverse reactions reported throughout clinical trials included infections and injection site reactions.
Trending: EPA's New Rules on Drug Disposal Begin in August
Administered via subcutaneous injection, starting dosage is 50 mg for all conditions; however, application frequency and combinations differ per condition.
Adult RA and PSA: 50 mg of subcutaneous etanercept-ykro is to be administered once weekly in conjunction with methotrexate.
AS: 50 mg of etanercept-ykro is administered only once weekly.
Adults with PsO: 50 mg of etanercept-ykro is administered twice weekly for three months, followed by 50 mg once weekly for the remaining treatment cycle.
Pediatric patients suffering from PsO or JIA and weigh 63 kg or more: 50 mg of etanercept-ykro once weekly.
